Clara M Pelfrey

Title: The Innovations of Clara M. Pelfrey in Multiple Sclerosis Research

Introduction

Clara M. Pelfrey, based in Gaithersburg, Maryland, is a notable inventor dedicated to advancing the understanding and treatment of multiple sclerosis. With a focus on innovative therapeutic approaches, Pelfrey’s work has led to the development of groundbreaking compositions that provide significant insights into this complex neurological condition.

Latest Patents

Clara M. Pelfrey holds a patent for "Modified myelin basic protein molecules." This patent outlines compositions and methods aimed at the clinical assessment, diagnosis, and treatment of multiple sclerosis. Specifically, the invention revolves around molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, including nucleic acids and polypeptides. These nucleic acid molecules facilitate the efficient production of both modified and unmodified 21.5 kDa myelin basic protein polypeptides, which bear relevance for assessing T cells' responsiveness to myelin basic protein epitopes. The polypeptides detailed in the patent also possess therapeutic potential, acting to induce T cell responses, including apoptosis, thereby contributing to the treatment landscape for multiple sclerosis.

Career Highlights

Throughout her career, Clara M. Pelfrey has collaborated with organizations, including the United States of America as represented by the Department of Health and Human Services and Alexion Pharmaceuticals, Inc. Her innovative contributions have positioned her as a respected figure in the field of multiple sclerosis research.

Collaborations

Pelfrey has worked alongside esteemed colleagues such as Steven H. Nye and Michael J. Lenardo, further enriching her work with a diverse range of expertise. These collaborations have likely enhanced the depth and impact of her research efforts.

Conclusion

Clara M. Pelfrey's contributions to the understanding and treatment of multiple sclerosis underline her significant role as an inventor and researcher. Her pioneering work with modified myelin basic protein molecules exemplifies the potential for innovations to lead to improved clinical outcomes for patients suffering from this challenging condition.